Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials

#870

Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.

Aim(s): There is limited information on the potential benefits of serotonin reduction in patients (pts) with CaHD.

Materials and methods: We retrospectively reviewed data on all pts who received TE in Phase 2 trials for CS. In pts with prior history of CaHD, we assessed baseline characteristics, reductions in u5-HIAA, adverse events (AEs), and procedures while on TE.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Wheeler D, Kulke M, O’Dorisio T, Hörsch D, Jackson S,

Keywords: carcinoid, heart disease, serotonin, telotristat,